Sientra expands its global footprint with regulatory approval to market breast implants in the United Arab Emirates

IRVINE, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) — Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced that it has received approval from the United Arab Emirates Ministry of Health and Prevention to market the company’s line of smooth surface, High-Strength Cohesive (HSC and HSC+) silicone gel breast implants in the United Arab Emirates. This new approval marks Sientra’s third international expansion this year.

“We are pleased to receive approval so quickly in the UAE, which is a strong testament to Sientra’s strong clinical and quality standards.” said Ron Menezes, President and Chief Executive Officer of Sientra, “We are excited about expanding our footprint even further in the GCC and are looking forward to providing patients and surgeons with both choice and safety.”

Sientra is proud of their ability to market breast implants in the GCC via Rose Aljazera (a long-standing distributor of medical aesthetics solutions in the Middle East for over 20 years).

“Having seen Sientra’s exceptional product and data, we’ve eagerly anticipated the introduction of this new breast technology for our patients,” said Dr. Zuhair Alfardan, plastic surgeon at Eternal Clinic in Dubai, UAE and President of the Emirates Plastic Surgery Society (EPSS).  “With Sientra’s outstanding 10-year clinical safety data, which is unrivaled in the UAE, we can’t wait to provide the latest in breast implant technology and give our patients the aesthetics results and experience that they deserve.”

About Sientra

Sientra, an exclusive medical aesthetics company, is based in Irvine, California. The Company’s mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has a wide portfolio of products that have technologically different characteristics. This is supported by strong clinical trial results and independent laboratory testing. The Company’s product portfolio includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2^® breast tissue expander with patented dual-port and integral drain technology, the Viality™ with Auraclens™ lipoaspirate wash system, and BIOCORNEUM^®The #1-performing, most preferred, and recommended scar gel for plastic surgeons

.www.sientra.comSientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at 

.www.sientra.caCanadian plastic surgeons can request additional information regarding Sientra silicone jelly breast implants. This includes important safety information. 

^.(*) 

Data on fileForward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements speak only as of the date this release. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Forward-looking statements may include information concerning the Company’s expansion into international markets, the Company’s prospects and opportunities in GCC and the Middle East for its breast implants, the adoption of the Company’s products in GCC and the Middle East by plastic surgeons and consumers, and Sientra’s continued growth in the United States and internationally. Such statements are subject to risks and uncertainties, including the positive reaction from plastic surgeons and their patients the Company’s products in the United States and internationally (including GCC and the Middle East), the Company’s ability to successfully leverage its commercial team and brand to generate significant breast implants sales in GCC and the Middle East, the Company’s ability to execute on its commercial, clinical and research and development plans for international expansion. Additional factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Sientra’s public filings with the Securities and Exchange Commission. Other than historical facts statements, all statements are forward-looking statements. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. These forward-looking information should not be relied on. Projections, estimates and other forward-looking statements are made as of the date that they were made. Except as required by law, the Company is not obligated to review, revise or update any estimate, projection or forward looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company’s business.
Contact for Investor Relations  
[email protected]

Aman R. Patel CFA
Media Contact
[email protected]